Maximillian J Hochmair

24PUBLICATIONS
89CO-AUTHORS
Epidemiological modellingPredictive and prognostic markersMolecular targetsCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|May 11, 2026
Structured Expert Elicitation of Long-Term Survival in Non-small Cell Lung Cancer: A Case Study Applying Guidance from NICE Technical Support Document 26.

|Jan 28, 2026
Clinical Impact of EGFR Mutation Subtypes on Treatment Outcomes in Advanced Non-Small Cell Lung Cancer: An Austrian Real-World Study.

Caroline Braschel, Hannah Fabikan, Vania Mikaela Rodriguez

|Nov 20, 2025
Preoperative selpercatinib induces major pathological response in a patient with stage IIIA, RET fusion-positive non-small cell lung cancer: A case report.

Kristina Breitenecker, Hannah Fabikan, Christoph Weinlinger

|Jul 12, 2025
The Efficacy of First-Line Pembrolizumab Monotherapy in Patients with Metastatic NSCLC Aged ≥70 Years with High PD-L1 (TPS ≥ 50%) Expression: A Multicenter Real-World Study.

Filip Marković, Maximilian Hochmair, Nino Müser

|Jun 03, 2025
Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer.

Maximilian Hochmair, Urpo Kiiskinen, Yulia D'yachkova

|Jan 25, 2025
Prevention and Treatment of Venous Thromboembolism Associated with Amivantamab-Based Therapies in Patients with Lung Cancer-Provisional Clinical Opinion Based on Existing Clinical Practice Guidelines.

Florian Moik, Gudrun Absenger, Robert Wurm

Pageof 4

Frequent Collaborators

9 joint publications

Oliver Illini

5 joint publications

Stefan Watzka

2 joint publications

Michal Benej

2 joint publications

Gerhard Hamilton